---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-335192"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2026-08-05T20:19:21+00:00"
generated_at: "2026-08-05T20:20:17.489301+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q2 2026 revenue up 19% to $119.6M; net loss $83.4M on $161M fair-value charge

## Summary
- Total revenue $119.6M (+19% YoY); net product sales $51.8M (+46% YoY) driven by IST growth.
- Net loss $83.4M ($1.14 loss per share) due to $161M unfavorable fair-value change in equity investments (Armata).
- Royalty revenue from GSK stable at $59.8M; IST U.S. net product sales $36.6M (+26% YoY).
- Launched Nortiva Bio for long-acting oral drug delivery; XACDURO licensing deal with Dr. Reddy's for emerging markets.
- Repurchased 1.4M shares for $31.4M in Q2; cash $570.4M.

## SEC filing metadata
- accession: 0001193125-26-335192
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2026-08-05T20:19:21+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000119312526335192/0001193125-26-335192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000119312526335192/d228097d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-335192
- JSON: https://secwatch.observer/filing/0001193125-26-335192.json
- Plain text: https://secwatch.observer/filing/0001193125-26-335192.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.